Samsung Biologics Co., Ltd. is a leading contract development and manufacturing organization (CDMO) that provides services for the biopharmaceutical industry. The company offers a wide range of services, including cell line development, process development, and manufacturing of biologic drugs. Samsung Biologics stock has been performing well in the market, driven by the increasing demand for biologic drugs and the company's strong track record in delivering high-quality services to its clients.
